Project Grant F30CA294839
- The University of Pittsburgh received a $585,931 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) on February 3, 2025. The grant will fund a comprehensive research framework to determine the molecular credentials and selection of cancer models, such as cell lines, patient-derived xenografts (PDX), and patient-derived organoids (PDO), to guide translational and clinical applications in breast cancer. The key objectives are: (1) identifying and...
- This $104,096 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) supports an integrated in silico and in vivo genetic screening approach to identify subtype-specific genetic dependencies for hepatocellular carcinoma (HCC). The award was made to the University of Pittsburgh and aims to determine if genetic dependencies predicted via deep learning demonstrate subtype specificity using in vivo loss-of-function screening, and to quantify...
- The University of Pittsburgh received a $180,632 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to conduct research on halting breast cancer metastasis. The project aims to discover and validate compounds that can block the engulfment of mesenchymal stem cells (MSCs) by breast cancer cells, as this process has been linked to increased tumor growth, metastasis, and chemotherapy resistance. Using microfluidic technology, the researchers will create a...
- This $150,104 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to understand the evolutionary trajectories of complex genomic rearrangements in cancer. The project aims to develop novel computational approaches, "AGAVE" and "ROSE", to characterize the timing and dynamics of focal amplifications and structural variants during tumor evolution. The research will map these evolutionary patterns across...
- This $292,028 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms by which oncogene amplification leads to genome instability and the development of therapy-resistant cancer clones. The research will be conducted by the Sloan-Kettering Institute for Cancer Research in New York and is scheduled to run from August 1, 2025 to July 31, 2030. Using single-cell genomic sequencing techniques, the project aims...
- This Project Grant, awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), provides $121,857 to the University of Pittsburgh to systematically investigate the impact of anti-cancer drugs on T cells within the tumor microenvironment. The award aims to identify novel drug combinations that can overcome resistance to immune checkpoint blockade therapies in cancer treatment. Specifically, the research will involve in silico screening of anti-cancer drugs for their...
- This Project Grant award, totaling $102,984, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The award supports research by The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, to perform spatio-temporal analyses of the entire brain-metastatic arc, from single-cell interaction with the blood-brain-barrier to fully developed brain metastases. The research will...
- This Project Grant award of $176,712.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Pittsburgh, supports research on immunosurveillance mechanisms that eliminate pre-cancerous cells prior to the formation of malignancies. The primary objective is to investigate how tumor-derived heat shock proteins (HSPs) engage the CD91 receptor on antigen-presenting cells, leading to priming of T cell responses against emerging tumors. This research...
- The National Cancer Institute (NCI) awarded a $591,468 Project Grant on August 6, 2025 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Research Foundation for the State University of New York (SUNY Oswego). The funding supports research to develop explainable machine learning models based on deep cancer pathophysiology to improve cancer diagnosis, risk stratification, and therapeutic recommendations. The project aims to address key gaps in integrating heterogeneous...
- This Cooperative Agreement award for $639,882, funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research at the University of North Carolina at Chapel Hill to elucidate the molecular mechanisms of metastasis organ tropism in breast cancer. The key objectives are to: Identify molecular determinants of lung and liver organ-specific metastasis using a comprehensive dataset of human primary tumors and metastases, as well as genetically...
This Project Grant award of $109,076 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to identify patterns of gene deletions in metastatic breast cancer. The award, which runs from January 21, 2026 to July 31, 2029, aims to leverage machine learning techniques and comprehensive autopsy data to create a detailed landscape of genomic evolution in late-stage metastatic disease. The research, conducted by the University of Pittsburgh, seeks to determine if genomic deletions can serve as landmarks for tracking tumor phylogeny and be targeted for new treatment approaches. This project builds on the university's expertise in cancer biology and access to unique metastatic tissue samples through collaborations with the Aurora US Metastasis Project and the University of Pittsburgh's Hope for Others rapid autopsy program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 7/21/25 | ||
| Not listed | $54.5k | 7/21/25 | ||
| Not listed | $54.5k | 7/21/25 |